Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 140

1.

Prenatal exposure to antidepressants and depressed maternal mood alter trajectory of infant speech perception.

Weikum WM, Oberlander TF, Hensch TK, Werker JF.

Proc Natl Acad Sci U S A. 2012 Oct 16;109 Suppl 2:17221-7. doi: 10.1073/pnas.1121263109. Epub 2012 Oct 8.

2.

Infant developmental outcomes following prenatal exposure to antidepressants, and maternal depressed mood and positive affect.

Hanley GE, Brain U, Oberlander TF.

Early Hum Dev. 2013 Aug;89(8):519-24. doi: 10.1016/j.earlhumdev.2012.12.012. Epub 2013 Feb 4.

PMID:
23384962
3.

The impact of prenatal serotonin reuptake inhibitor (SRI) antidepressant exposure and maternal mood on mother-infant interactions at 3 months of age.

Weikum WM, Mayes LC, Grunau RE, Brain U, Oberlander TF.

Infant Behav Dev. 2013 Dec;36(4):485-93. doi: 10.1016/j.infbeh.2013.04.001. Epub 2013 May 30.

PMID:
23728194
4.

Prenatal antidepressant exposure associated with CYP2E1 DNA methylation change in neonates.

Gurnot C, Martin-Subero I, Mah SM, Weikum W, Goodman SJ, Brain U, Werker JF, Kobor MS, Esteller M, Oberlander TF, Hensch TK.

Epigenetics. 2015;10(5):361-72. doi: 10.1080/15592294.2015.1026031. Epub 2015 Apr 18.

5.

Neurodevelopmental outcomes following prenatal exposure to serotonin reuptake inhibitor antidepressants: a "social teratogen" or moderator of developmental risk?

Hanley GE, Oberlander TF.

Birth Defects Res A Clin Mol Teratol. 2012 Aug;94(8):651-9. doi: 10.1002/bdra.23032. Epub 2012 Jun 26. Review.

PMID:
22733632
6.

Impact of prenatal exposure to serotonin reuptake inhibitors or maternal major depressive disorder on infant developmental outcomes.

Santucci AK, Singer LT, Wisniewski SR, Luther JF, Eng HF, Dills JL, Sit DK, Hanusa BH, Wisner KL.

J Clin Psychiatry. 2014 Oct;75(10):1088-95. doi: 10.4088/JCP.13m08902.

PMID:
25373117
8.

Neurobehavioral assessment of infants born at term and in utero exposure to serotonin reuptake inhibitors.

Smith MV, Sung A, Shah B, Mayes L, Klein DS, Yonkers KA.

Early Hum Dev. 2013 Feb;89(2):81-6. doi: 10.1016/j.earlhumdev.2012.08.001. Epub 2012 Sep 20.

9.

The effect of perinatal exposures on the infant: antidepressants and depression.

Hanley GE, Oberlander TF.

Best Pract Res Clin Obstet Gynaecol. 2014 Jan;28(1):37-48. doi: 10.1016/j.bpobgyn.2013.09.001. Epub 2013 Sep 18. Review.

PMID:
24100223
10.

Hypothalamic-pituitary-adrenal (HPA) axis function in 3-month old infants with prenatal selective serotonin reuptake inhibitor (SSRI) antidepressant exposure.

Oberlander TF, Grunau R, Mayes L, Riggs W, Rurak D, Papsdorf M, Misri S, Weinberg J.

Early Hum Dev. 2008 Oct;84(10):689-97. doi: 10.1016/j.earlhumdev.2008.06.008. Epub 2008 Jul 18.

11.

Neonatal Discontinuation Syndrome in Serotonergic Antidepressant-Exposed Neonates.

Yang A, Ciolino JD, Pinheiro E, Rasmussen-Torvik LJ, Sit DKY, Wisner KL.

J Clin Psychiatry. 2017 May;78(5):605-611. doi: 10.4088/JCP.16m11044.

PMID:
28570796
12.

Acute and long-term behavioral outcome of infants and children exposed in utero to either maternal depression or antidepressants: a review of the literature.

Suri R, Lin AS, Cohen LS, Altshuler LL.

J Clin Psychiatry. 2014 Oct;75(10):e1142-52. doi: 10.4088/JCP.13r08926. Review.

PMID:
25373125
13.

Child development following exposure to tricyclic antidepressants or fluoxetine throughout fetal life: a prospective, controlled study.

Nulman I, Rovet J, Stewart DE, Wolpin J, Pace-Asciak P, Shuhaiber S, Koren G.

Am J Psychiatry. 2002 Nov;159(11):1889-95.

PMID:
12411224
14.

Prenatal SSRI exposure alters neonatal corticosteroid binding globulin, infant cortisol levels, and emerging HPA function.

Pawluski JL, Brain UM, Underhill CM, Hammond GL, Oberlander TF.

Psychoneuroendocrinology. 2012 Jul;37(7):1019-28. doi: 10.1016/j.psyneuen.2011.11.011. Epub 2011 Dec 15.

PMID:
22177580
15.

Association of Selective Serotonin Reuptake Inhibitor Exposure During Pregnancy With Speech, Scholastic, and Motor Disorders in Offspring.

Brown AS, Gyllenberg D, Malm H, McKeague IW, Hinkka-Yli-Salomäki S, Artama M, Gissler M, Cheslack-Postava K, Weissman MM, Gingrich JA, Sourander A.

JAMA Psychiatry. 2016 Nov 1;73(11):1163-1170. doi: 10.1001/jamapsychiatry.2016.2594.

PMID:
27732704
16.

Prenatal effects of selective serotonin reuptake inhibitor antidepressants, serotonin transporter promoter genotype (SLC6A4), and maternal mood on child behavior at 3 years of age.

Oberlander TF, Papsdorf M, Brain UM, Misri S, Ross C, Grunau RE.

Arch Pediatr Adolesc Med. 2010 May;164(5):444-51. doi: 10.1001/archpediatrics.2010.51.

PMID:
20439795
17.

Pain reactivity in 2-month-old infants after prenatal and postnatal serotonin reuptake inhibitor medication exposure.

Oberlander TF, Grunau RE, Fitzgerald C, Papsdorf M, Rurak D, Riggs W.

Pediatrics. 2005 Feb;115(2):411-25.

PMID:
15687451
18.

Neonatal growth outcomes at birth and one month postpartum following in utero exposure to antidepressant medication.

Lewis AJ, Galbally M, Opie G, Buist A.

Aust N Z J Psychiatry. 2010 May;44(5):482-7. doi: 10.3109/00048670903559593.

PMID:
20397792
19.

Neurodevelopment of children following prenatal exposure to venlafaxine, selective serotonin reuptake inhibitors, or untreated maternal depression.

Nulman I, Koren G, Rovet J, Barrera M, Pulver A, Streiner D, Feldman B.

Am J Psychiatry. 2012 Nov;169(11):1165-74. doi: 10.1176/appi.ajp.2012.11111721.

PMID:
23128923
20.

Prenatal exposure to maternal depression, neonatal methylation of human glucocorticoid receptor gene (NR3C1) and infant cortisol stress responses.

Oberlander TF, Weinberg J, Papsdorf M, Grunau R, Misri S, Devlin AM.

Epigenetics. 2008 Mar-Apr;3(2):97-106.

PMID:
18536531

Supplemental Content

Support Center